Stock Ratings / Health Care / CTKB / financials

PACB (37) NAUT (41) ALMR (48) LAB (41) ⌘ Pro Terminal →

Cytek Biosciences Inc. (CTKB) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$6.30 +2.61% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $6.32

Cytek Biosciences Inc. (CTKB) carries a Roarable Rating of D- (Sell) with 41/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (41/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • RED ALERT Cap $818.9M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $6.32 (+0.28%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (41/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.2% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-7.6% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CTKB)Realized 20D OHLCV Swing Band: ±11.7%

Deterministic 5-Pillar Attribution (41/100 Composite)

🔍 WHY CTKB SCORES 41/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+11/20 pts (27% of score)

20D Institutional Volume Accumulation (±11.7% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+11/20 pts (27% of score)

Altman Z-Score 4.76 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$5.43-3.3% Next Q

Q2 (-2Q)

Grade E$5.25+6.5% Next Q

Q3 (-1Q)

Grade E$5.59+12.7% Next Q

Current

Grade D-$6.30-7.2% Hist 90D α

Trajectory: E (33) → D- (41)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a CTKB Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While CTKB currently carries a cautious 41/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($5.28) and Max Pain ($6.62) forces dealer call-delta covering toward $6.87.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $CTKB• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “CTKB Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 41%NO 59%Trade / Inspect Odds →

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How CTKB Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$0 (0% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $193.0M

FY24

Rev $200.5M

FY25

Rev $201.5M

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$201.5M	51.8%	-20%	-$66.5M	-$8.8M	-12.7%
FY 2024	$200.5M	55.4%	-10.2%	-$6.0M	$21.9M	-5.5%
FY 2023	$193.0M	51.8%	-14.4%	-$12.1M	$5.3M	-12.7%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CTKB)

✓Walkthrough of CTKB's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

CTKB // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +38.16%▲ ASCENDING CHANNEL

2026-10-30O $6.26H $6.30L $6.05C $6.30VOL 1.87M

RES: $6.59SUP: $4.83SMA50: $5.28SMA200: $4.65

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CTKB Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 CTKB Butterfly Map → + Track CTKB →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +0.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on CTKB today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for CTKB. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for CTKB today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CTKB)

Health Care Rank #607 of 1016 ⚔️ PACB vs CTKB Full Matrix →

1. Head-to-Head Health Care Peer Comparison (CTKB vs. PACB, NAUT, ALMR, LAB)

Industry: Biotechnology: Laboratory Analytical Instruments (21 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Cytek Biosciences Inc. (CTKB) ranks #607 by composite RQD confidence (41/100, grade D-) and #384 by equity capitalization ($818.9M). Within this direct 5-issuer industry benchmark cohort, CTKB leads on earnings valuation at N/A trailing P/E, while CTKB leads on capital efficiency and profitability with -12.7% ROIC and 51.8% gross margin. ALMR currently holds the highest overall quantitative score in the immediate peer group at 48/100 (D) compared with CTKB at 41/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
CTKB ACTIVE Cytek Biosciences Inc.	D-	41/100	—	51.8%	-12.7%	+2.61%	$818.9M	Benchmark Subject
PACB Pacific Biosciences of California Inc.	D-	37/100	—	28.6%	-35.0%	+2.47%	$901.4M	/pacb-vs-ctkb →
NAUT Nautilus Biotechnology Inc.	D-	41/100	—	—	-35.0%	-2.18%	$399.9M	/naut-vs-ctkb →
ALMR Alamar Biosciences Inc.	D	48/100	—	—	—	-0.76%	$2.36B	/almr-vs-ctkb →
LAB Standard BioTools Inc.	D-	41/100	—	49.9%	-28.7%	+0.49%	$244.7M	/lab-vs-ctkb →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001831915

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Cytek Biosciences Inc. (CTKB) reported GAAP revenue of $201.5M (+0.5% vs. FY2024 revenue of $200.5M , and +4.4% cumulative change since FY2023) , GAAP net income of -$66.5M, operating cash flow of -$4.7M, and free cash flow of -$8.8M (-140.1% YoY). On the balance sheet, CTKB closed FY2025 with $461.5M in total assets against $0 in total debt (Altman Z-Score: 4.76, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$201.5M	-$66.5M	-$4.7M	-$8.8M	$461.5M	—
FY2024 (FY)	2024-12-31	$200.5M	-$6.0M	$25.4M	$21.9M	$499.5M	—
FY2023 (FY)	2023-12-31	$193.0M	-$12.1M	$5.3M	$5.3M	—	—

3. CTKB Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CTKB stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Cytek Biosciences Inc. (NASDAQ: CTKB) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 41/100 at a spot price of $6.30 (+2.61% 1D, market cap $818.9M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, CTKB ranks #607 in composite RQD confidence.

How does CTKB compare to PACB and NAUT in the Health Care sector?

Within the Health Care sector (Biotechnology: Laboratory Analytical Instruments), CTKB carries a Roarable D- (41/100 RQD), trailing P/E of N/A, gross margin of 51.8%, and ROIC of -12.7%. By comparison, PACB (Pacific Biosciences of California Inc.) holds a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $901.4M) and NAUT (Nautilus Biotechnology Inc.) posts a D- grade (41/100 RQD, P/E N/A, ROIC -35.0%, cap $399.9M). Among the 5-stock peer group, CTKB leads on earnings multiple (N/A) while CTKB leads on capital efficiency (-12.7% ROIC).

What are the biggest fundamental strengths and SEC risk factors for CTKB?

Per CTKB's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001831915), Cytek Biosciences Inc. generated $201.5M in revenue (+0.5% YoY), -$66.5M in net income, and -$8.8M in free cash flow against $461.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is CTKB trading relative to its 50-day, 200-day, and 52-week technical levels?

CTKB last traded at $6.30 (+2.61% on volume of 1,914,850 shares), positioning the stock +19.32% above its 50-day simple moving average ($5.28) and +35.48% above its 200-day simple moving average ($4.65). Across its 52-week range of $3.31 to $6.34, CTKB sits at the 98.7% percentile with a 14-day RSI of 65.6 (BULLISH MOMENTUM) and an implied next-earnings move of ±11.7% ($5.56 to $7.04).

CTKB Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

How profitable is Cytek Biosciences Inc. (CTKB)?

In FY 2025 (10-K), CTKB converted $201.5M of revenue into a 51.8% gross margin, 0% operating margin, and $0 in free cash flow (0% FCF margin).

Direct Sub-Reports: CTKB RQD Cockpit CTKB 12M Forecast CTKB Earnings & Move CTKB Dividends & DRIP CTKB Insiders & 13F CTKB Whale Options CTKB Profit Sankey CTKB News & Why